Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (currently amended) A compound of formula (1):



(1)

wherein:

n is 0, 1, or 2;

m is 0, 1, or 2;

R^1 is independently selected from hydrogen, halo, nitro, cyano, hydroxy, amino, carboxy, carbamoyl, *N*-C_{1-4}alkylcarbamoyl, *N*,*N*-(C_{1-4}alkyl)$_2$carbamoyl, sulphamoyl, *N*-C_{1-4}alkylsulphamoyl, *N*,*N*-(C_{1-4}alkyl)$_2$sulphamoyl, C_{1-4}alkyl, C_{2-4}alkenyl, C_{2-4}alkynyl, C_{1-4}alkoxy, C_{1-4}alkanoyl, C_{1-4}alkanoyloxy, *N*-(C_{1-4}alkyl)amino, *N*,*N*-(C_{1-4}alkyl)$_2$amino, hydroxyC_{1-4}alkyl, fluoromethyl, difluoromethyl, trifluoromethyl, trifluoromethoxy, and groups of the formula A or A':



(A)



(A')

wherein x is 0 or 1, r is 0, 1, 2, or 3, s is 1 or 2 and u is 1 or 2; provided that the hydroxy group is not a substituent on the ring carbon adjacent to the ring oxygen;

R^4 is independently selected from hydrogen[[,]] or halo~~, nitro, cyano, hydroxy, fluoromethyl, difluoromethyl, trifluoromethyl, trifluoromethoxy, carboxy, carbamoyl, C_{1-4}alkyl, C_{2-4}alkenyl, C_{2-4}alkynyl, C_{1-4}alkoxy, and C_{1-4}alkanoyl~~;

B is phenyl ~~or heterocyclyl~~;

R^{14} is selected from hydrogen, halo, C_{1-4}alkyl (optionally substituted with 1 or 2 hydroxy groups), C_{5-7}cycloalkyl (optionally substituted with 1 or 2 hydroxy groups), C_{1-4}alkoxy, cyano, cyano(C_{1-4})alkyl, -COR^3, (R^2)(R^3)NCO-, and (R^2)(R^3)NSO_2-;

R^2 and R^3 are independently selected from C_{5-7}cycloalkyl (optionally substituted with 1 or 2 hydroxy groups), cyano(C_{1-4})alkyl, 5- and 6-membered cyclic acetals and mono- and di-methyl derivatives thereof, tetrahydrothiopyranyl, 1-oxotetrahydrothiopyranyl, 1,1-dioxotetrahydrothiopyranyl, fluoromethylcarbonyl, difluoromethylcarbonyl, trifluoromethylcarbonyl, C_{1-4}alkyl (optionally substituted with 1 or 2 R^8 groups), –OR^8, and R^8;

R^8 is independently selected from hydrogen, 2,2-dimethyl-1,3-dioxolan-4-yl, heterocyclyl (optionally substituted on ring carbon or ring nitrogen with 1 or 2 groups selected from hydrogen, nitro, halo, cyano, hydroxy, and C_{1-4}alkyl), (heterocyclyl)C_{1-4}alkyl (wherein the heterocyclyl is optionally substituted on ring carbon or ring nitrogen with 1 or 2 groups selected from hydrogen, nitro, halo, cyano, hydroxy, and C_{1-4}alkyl), aryl (optionally substituted with 1 or 2 groups selected from nitro, halo, cyano, hydroxy, and C_{1-4}alkyl), C_{1-4}alkyl, C_{2-4}alkenyl, cyclo(C_{3-8})alkyl, C_{1-4}alkoxy, cyano(C_{1-4})alkyl, amino(C_{1-4})alkyl (optionally substituted on nitrogen with 1 or 2 groups selected from hydrogen, C_{1-4}alkyl, hydroxy, hydroxy(C_{1-4})alkyl, dihydroxy(C_{1-4})alkyl, aryl and aryl(C_{1-4})alkyl), C_{1-4}alkyl$S(O)_c$(C_{1-4})alkyl (wherein c is 0, 1 or 2), -N(OH)CHO, $-CH_2CH(CO_2R^9)N(R^9R^{10})$, $-CH_2OR^9$, (R^9)(R^{10})N-, –$COOR^9$, $-CH_2COOR^9$, –$CH_2CONR^9R^{10}$, and $-(CH_2)_uCH(NR^9R^{10})CO_2R^9$ (wherein u is 1, 2, or 3);

R^9 and R^{10} are independently selected from hydrogen, hydroxy, C_{1-4}alkyl (optionally substituted with 1 or 2 hydroxy groups), C_{5-7}cycloalkyl (optionally substituted with 1 or 2 hydroxy groups), C_{2-4}alkenyl, cyano(C_{1-4})alkyl, tetrahydrothiopyranyl, 1-oxotetrahydrothiopyranyl, 1,1-dioxotetrahydrothiopyranyl, 2,2-dimethyl-1,3-dioxolan-4-yl, aryl (optionally substituted with 1 or 2 substituents selected from hydrogen, nitro, halo, hydroxy, and C_{1-4}alkyl), and C_{1-4}alkyl substituted with R^{13}; or

R^9 and R^{10} together with the nitrogen to which they are attached form a 4- to 6-membered ring where the ring is optionally substituted on carbon with 1 or 2 substituents selected from oxo, hydroxy, carboxy, halo, nitro, nitroso, cyano, isocyano, amino, *N*-C_{1-4}alkylamino, *N,N*-(C_{1-4}alkyl)$_2$amino, carbonyl, C_{1-4}alkoxy, heterocyclyl, C_{1-4}alkanoyl, C_{1-4}alkyl$S(O)_f$(C_{1-4})alkyl (wherein f is 0, 1, or 2), -N(OH)CHO, (R^{11})(R^{12})NCO-, (R^{11})(R^{12})NSO_2-, $-COCH_2OR^{11}$, and (R^{11})(R^{12})N-;

R^{13} is selected from hydroxy, C_{1-4}alkoxy, heterocyclyl, C_{1-4}alkanoyl, C_{1-4}alkyl$S(O)_d$ (wherein d is 0, 1, or 2), -N(OH)CHO, -C(O)N(R^{11})(R^{12}), (R^{11})(R^{12})NSO_2-, $-COCH_2OR^{11}$, and (R^{11})(R^{12})N-; and

R^{11} and R^{12} are independently selected from hydrogen, C_{1-4}alkyl, C_{1-4}alkoxy, hydroxyC_{1-4}alkyl, and C_{1-4}alkyl$S(O)_e$ (wherein e is 0, 1, or 2);
or a pharmaceutically acceptable salt or prodrug thereof.

2-3. (cancelled)

4. (original) A compound of claim 1 wherein:

n is 1 or 2;

R^1 is independently selected from hydrogen, halo, nitro, hydroxy, C_{1-4}alkyl, or R^1 is of the formula A or A':



(A')



(A")

wherein x is 0 or 1, r is 0, 1, 2, or 3, s is 1 or 2 and u is 1 or 2; provided that the hydroxy group is not a substituent on the ring carbon adjacent to the ring oxygen;

B is phenyl;

R^{14} is selected from C_{1-4}alkyl, cyano(C_{1-4})alkyl, -COR^3, $(R^2)(R^3)NCO$-, and $(R^2)(R^3)NSO_2$-;

R^2 and R^3 are independently selected from C_{1-4}alkyl, C_{1-4}alkyl (substituted with R^8), $-OR^8$, and R^8;

R^8 is independently selected from hydrogen, heterocyclyl (optionally substituted on carbon or nitrogen with 1 or 2 groups selected from nitro, halo, hydroxy, cyano, and C_{1-4}alkyl), (heterocyclyl)(C_{1-4})alkyl (optionally substituted on carbon or nitrogen with 1 or 2 groups selected from nitro, halo, hydroxy, cyano, and C_{1-4}alkyl), aryl (optionally substituted with 1 or 2 groups selected from nitro, halo, cyano, hydroxy, and C_{1-4}alkyl), C_{1-4}alkyl, C_{2-4}alkenyl, cyclo(C_{3-8})alkyl, C_{1-4}alkoxy, cyano(C_{1-4})alkyl, amino(C_{1-4})alkyl (optionally substituted on nitrogen with 1 or 2 groups selected from hydrogen, C_{1-4}alkyl, hydroxy, hydroxy(C_{1-4})alkyl, dihydroxy(C_{1-4})alkyl, aryl, and aryl(C_{1-4})alkyl), C_{1-4}alkyl$S(O)_c(C_{1-4})$alkyl (wherein c is 0, 1, or 2), $-(CH_2)_uCH(CO_2R^9)N(R^9R^{10})$ (wherein u is 0, 1, or 2), $-CH_2OR^9$, $(R^9)(R^{10})N$-, $-COOR^9$,$-CH_2COOR^9$, $-CH_2CONR^9R^{10}$, and $-CH_2CH_2CH(NR^9R^{10})CO_2R^9$;

R^9 and R^{10} are independently selected from hydrogen, C_{1-4}alkyl (optionally substituted with1 or 2 hydroxy groups), C_{5-7}cycloalkyl (optionally substituted with 1 or 2 hydroxy groups),

C_{2-4}alkenyl, cyano(C_{1-4})alkyl, and phenyl (optionally substituted with 1 or 2 groups selected from nitro, halo, hydroxy, and cyano);

m is 1;

R^4 is chloro;

or a pharmaceutically acceptable salt or in-vivo hydrolysable ester thereof.

5. (cancelled)

6. (original) A pharmaceutical composition which comprises a compound of claim 1, or a pharmaceutically acceptable salt or in-vivo hydrolysable ester thereof in association with a pharmaceutically acceptable diluent or carrier.

7. (original) A method for the treatment of type 2 diabetes, insulin resistance, syndrome X, hyperinsulinaemia, hyperglucagonaemia, cardiac ischaemia or obesity in a warm-blooded animal, comprising administering a compound of claim 1, or a pharmaceutically acceptable salt or in-vivo hydrolysable ester thereof.

8. (original) A method for the treatment of type 2 diabetes in a warm-blooded animal, comprising administering a compound of claim 1, or a pharmaceutically acceptable salt or in-vivo hydrolysable ester thereof.

9. (original) A process for the preparation of claim 1, which process comprises:
reacting an acid of the formula (2)



(2)

or an activated derivative thereof; with an amine of formula (3)



(3)

and thereafter if necessary

i) converting a compound of the formula (1) into another compound of the formula (1);

ii) removing any protecting groups; or

iii) forming a pharmaceutically acceptable salt or in-vivo hydrolysable ester.